Vineet Laboratories Limited (VINEETLAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vineet Laboratories Limited (VINEETLAB) has a cash flow conversion efficiency ratio of 0.035x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs12.24 Million ≈ $132.37K USD) by net assets (Rs348.52 Million ≈ $3.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Vineet Laboratories Limited to measure how much of total assets are equity-financed.
Vineet Laboratories Limited - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Vineet Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vineet Laboratories Limited cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Vineet Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vineet Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Puri Global Sukses Tbk Pt
JK:PURI
|
-0.151x |
|
Intanwijaya Internasional Tbk
JK:INCI
|
0.079x |
|
Khaitan (India) Limited
NSE:KHAITANLTD
|
0.010x |
|
DarkIris Inc. Class A Ordinary Shares
NASDAQ:DKI
|
N/A |
|
Touchwood Entertainment Limited
NSE:TOUCHWOOD
|
-0.092x |
|
Mason Graphite Inc.
V:LLG
|
-0.007x |
|
PYRAMID AG NA KONV.
XETRA:M3B0
|
0.092x |
|
PATRYS Ltd
AU:PAB
|
-2.365x |
Annual Cash Flow Conversion Efficiency for Vineet Laboratories Limited (2020–2025)
The table below shows the annual cash flow conversion efficiency of Vineet Laboratories Limited from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Vineet Laboratories Limited worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs146.48 Million ≈ $1.58 Million |
Rs114.91 Million ≈ $1.24 Million |
0.784x | +512.06% |
| 2024-03-31 | Rs347.24 Million ≈ $3.76 Million |
Rs-66.11 Million ≈ $-714.94K |
-0.190x | +33.31% |
| 2023-03-31 | Rs336.83 Million ≈ $3.64 Million |
Rs-96.16 Million ≈ $-1.04 Million |
-0.285x | -222.92% |
| 2022-03-31 | Rs332.18 Million ≈ $3.59 Million |
Rs77.15 Million ≈ $834.34K |
0.232x | +170.95% |
| 2021-03-31 | Rs266.15 Million ≈ $2.88 Million |
Rs-87.12 Million ≈ $-942.20K |
-0.327x | -4160.69% |
| 2020-03-31 | Rs3.99 Million ≈ $43.14K |
Rs-30.65K ≈ $-331.44 |
-0.008x | -- |
About Vineet Laboratories Limited
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl… Read more